How many patents does
Idera Pharmaceuticals have?
patents
482
families
61
granted
122
applications
360
US
125
EP
94
WO
51
CN
37
JP
20
KR
19
RoW
136
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Idera Pharmaceuticals
Top ten assignees appearing on patents
2009 - 2018
| idera pharmaceuticals | 420 |
| hybridon | 13 |
| edela medicaments company | 2 |
| the immune response corporation | 2 |
| adler drug company | 1 |
| idera pharmaceutials | 1 |
2018
| idera pharmaceuticals | 17 |
Idera Pharmaceuticals
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| novel synthetic agonists of tlr9 | 32 | 2007 |
| immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based i… 🛈 | 27 | 2010 |
| immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based i… 🛈 | 27 | 2005 |
| composition for inhibiting gene expression and uses thereof | 23 | 2009 |
| stabilized immune modulatory rna (simra) compounds | 21 | 2007 |
| immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based i… 🛈 | 20 | 2013 |
| stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 | 19 | 2006 |
| immunostimulatory oligonucleotide multimers | 15 | 2004 |
| modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by… 🛈 | 13 | 2000 |
| immunostimulatory properties of oligonucleotide-based compounds comprising modified immu… 🛈 | 12 | 2005 |